Evolent Health Inc Class A EVH 深 沪
已收盘 04-02 16:00:00 美东时间
2.25
+0.030
+1.35%
华盛通- 最 高2.25
- 今 开2.18
- 成交量 249.01万股
- 最 低 2.095
- 昨 收 2.22
- 总市值 2.51亿
- 52周最高 12.065
- 市盈率 静 --
- 换手率 2.23%
- 52周最低 2.095
- 委 比 -99.41%
- 总股本 1.12亿
- 历史最高 39.779
- 量 比 0.94
- 振 幅 6.98%
- 历史最低 2.095
- 每 手 1
- 风险率 2.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evolent Health appoints Archie Mayani as chief product officer
Evolent Health appoints Archie Mayani as chief product officer Evolent appointed Archie Mayani as chief product officer. Mayani previously served as chief product officer at GHX and Change Healthcare. Her earlier roles included leadership positions at Optum and UnitedHealth Group, and global head of
03-19 20:45
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Evolent Health Charts Growth Amid 2026 Margin Squeeze
Evolent Health Inc. (($EVH)) has held its Q4 earnings call. Read on for the mai...
03-01 08:11
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Evolent Health downgraded at KeyBanc on EBITDA recovery concerns
KeyBanc Capital Markets downgraded Evolent Health (EVH) to sector weight from overweight citing concerns over the company's EBITDA moving forward. The bank does not have a price target. KeyBanc's note...
02-25 23:50
This First Solar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-25 20:06
Keybanc Downgrades Evolent Health to Sector Weight
Keybanc analyst Matthew Gillmor downgrades Evolent Health (NYSE:EVH) from Overweight to Sector Weight.
02-25 19:25
财报速睇 | Evolent Health Inc Class A 2025财年年度营收18.76亿美元，同比下降26.6%；归母净利润亏损5.79亿美元，同比亏损扩大522.6%
华盛资讯2月25日讯，Evolent Health Inc Class A公布2025财年年度业绩，公司年度营收18.76亿美元，同比下降26.6%，归母净利润亏损5.79亿美元，同比亏损扩大522.6%。
02-25 19:16
BTIG Maintains Buy on Evolent Health, Lowers Price Target to $8
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $8.
02-25 17:50
